AMGEN INC — Director's Dealing 2022

Mar 4, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2022-03-01

Reporting Person: Gordon Murdo (EVP Global Commercial Ops)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-01	Common Stock	A	9989	—	Acquired	49682	Direct

Footnotes

F1: These shares include the following Restricted Stock Units granted under the Company's equity plans: 3,023 RSUs which vest in installments of 1,489 on 5/3/2022 and 1,534 on 5/3/2023; 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024; and 4,172 RSUs which vest in installments of 1,376 on 4/30/2023, 1,377 on 4/30/2024 and 1,419 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2: These shares include 538 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.